+44 20 8123 2220
info@marketpublishers.com

Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021

https://marketpublishers.com/r/F7854238E702EN.html
Date: April 2021
Pages: 35
Price: US$ 2,000.00 (Single User License)
ID: F7854238E702EN

Abstracts

Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021

SUMMARY

Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021 provides an overview of the Familial Chylomicronemia (Type I Hyperlipoproteinemia) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Familial Chylomicronemia (Type I Hyperlipoproteinemia), complete with analysis by Stage of Development, Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive Pharmacological Action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) and features dormant and discontinued projects.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries,

+44 20 8123 2220
info@marketpublishers.com

conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

NOTE:

* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.

SCOPE

The report provides a snapshot of the Global Therapeutic Landscape of Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders).

The report reviews pipeline therapeutics for Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The report covers pipeline products based on various stages of development ranging from discovery till pre-registration.

The report features descriptive drug profiles for the pipeline products which includes, Product Description, Descriptive MoA, R&D Brief, Licensing and Collaboration details & Other Developmental Activities.

The report reviews key players involved in the development of Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The report assesses Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) therapeutics based on Drug Target, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type.

+44 20 8123 2220
info@marketpublishers.com

The report summarizes all the dormant and discontinued pipeline projects.

The report reviews latest news related to pipeline therapeutics for Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders).

REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective Research and Development (R&D) strategies.

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Identify and understand important and diverse types of therapeutics under development for Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders).

Identify potential new clients or partners in the target demographic.

Develop strategic initiatives by understanding the focus areas of leading companies.

Plan Mergers and Acquisitions (M&A) effectively by identifying key players and it’s most promising pipeline therapeutics.

Devise corrective measures for pipeline projects by understanding Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

+44 20 8123 2220
info@marketpublishers.com

Contents

Introduction
Global Markets Direct Report Coverage
Indication - Overview
Indication - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Indication - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Indication - Companies Involved in Therapeutics Development
Company 1
Company 2
Company 3
Company XX
Indication - Drug Profiles
Drug 1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug 2 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug 3 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug 4 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug XX - Drug Profile

+44 20 8123 2220
info@marketpublishers.com

Product Description
Mechanism of Action
R&D Progress
Indication - Dormant Projects
Indication - Discontinued Products
Indication - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Number of Products under Development for Indication, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Products under Development by Companies, 2021
Products under Development by Universities/Institutes, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Indication - Pipeline by Company 1, 2021
Indication - Pipeline by Company 2, 2021
Indication - Pipeline by Company 3, 2021
Indication - Pipeline by Company XX, 2021
Indication - Dormant Projects, 2021
Indication - Discontinued Products, 2021

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Number of Products under Development for Indication, 2021
Number of Products under Development by Companies, 2021
Number of Products under Development by Universities/Institutes, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Top 10 Molecule Types, 2021
Number of Products by Stage and Top 10 Molecule Types, 2021

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Familial Chylomicronemia (Type I Hyperlipoproteinemia) (Metabolic Disorders) - Drugs in Development, 2021

Product link: https://marketpublishers.com/r/F7854238E702EN.html

Price: US$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/F7854238E702EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

+44 20 8123 2220
info@marketpublishers.com